Antoinette Moran
University of Minnesota
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Antoinette Moran as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:51 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06177691 · Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer): Extension StudyJaeb Center for Health Research · completed · Type1 Diabetes · study chair
- Ph4NCT05454176 · Diabetes in African YouthUniversity of Minnesota · active not recruiting · type1diabetes · principal investigator
- Ph3NCT04233034 · Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 DiabetesJaeb Center for Health Research · completed · Type1 Diabetes · study chair
- Ph2/Ph3NCT02496780 · The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis PatientsUniversity of Minnesota · terminated · Cystic Fibrosis · principal investigator
- Ph3NCT00222521 · Insulin Glargine Vs Standard Insulin TherapyUniversity of Minnesota · completed · Cystic Fibrosis Related Diabetes · principal investigator
- N/ANCT00222508 · The Microvascular Complications StudyUniversity of Minnesota · completed · Cystic Fibrosis Related Diabetes · principal investigator
- Ph3NCT00072904 · Diabetes Therapy to Improve BMI and Lung Function in CFNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · completed · Cystic Fibrosis, Diabetes Mellitus · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Diabetes in African Youth: Improving Glucose Time-In-RangeR01DK126726 · NIDDK · UNIVERSITY OF MINNESOTA · fiscal years 2022 to 2026 · $271,939 awarded in 2026Same name and institution; not confirmed by an ID
- Pre-faculty Research Training in Pediatric EndocrinologyT32DK065519 · NIDDK · UNIVERSITY OF MINNESOTA · fiscal years 2004 to 2022 · $172,227 awarded in 2022Same name and institution; not confirmed by an ID
- The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic CF PatientsR01DK101402 · NIDDK · UNIVERSITY OF MINNESOTA · fiscal years 2015 to 2019 · $685,689 awarded in 2019Same name and institution; not confirmed by an ID
- Type 1 Diabetes-A Proposal for Prevention & InterventionU01DK085476 · NIDDK · UNIVERSITY OF MINNESOTA · fiscal years 2009 to 2018 · $793,334 awarded in 2018Same name and institution; not confirmed by an ID
- ORAL INSULIN FOR PREVENTION OF DIABETES IN RELATIVES AT RISK FOR TYPE 1 DIABETESM01RR000400 · NCRR · UNIVERSITY OF MINNESOTA · fiscal years 1996 to 2009 · $5,854 awarded in 2009Same name and institution; not confirmed by an ID
- Type 1 Diabetes-A Proposal for Prevention & InterventionU01DK061036 · NIDDK · UNIVERSITY OF MINNESOTA · fiscal years 2004 to 2007 · $1,018,460 awarded in 2007Same name and institution; not confirmed by an ID
- Diabetes Therapy to Improve BMI and Lung Function in CFR01DK058356 · NIDDK · UNIVERSITY OF MINNESOTA · fiscal years 2001 to 2005 · $651,916 awarded in 2005Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:51 UTC. The ranking covers the 200 most relevant of 70 PubMed records, and a shared surname and initials can bring in a namesake. All 70 on PubMed
- An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.N Engl J Med · 2019945 citationsRCR 36.0
- Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.N Engl J Med · 2009865 citationsRCR 19.1
- 498 citationsRCR 11.8
- 309 citationsRCR 8.6
- Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals.Sci Transl Med · 2021306 citationsRCR 16.9
- 302 citationsRCR 7.2
- B-lymphocyte depletion with rituximab and β-cell function: two-year results.Diabetes Care · 2014237 citationsRCR 6.8
- 198 citationsRCR 10.1
- Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial.Diabetes Care · 2009190 citationsRCR 5.5
- 183 citationsRCR 8.4